Volume 27, Number 6—June 2021
Dispatch
Molecular Characterization and Antimicrobial Resistance in Neisseria gonorrhoeae, Nunavut Region of Inuit Nunangat, Canada, 2018–2019
Ameeta E. Singh
, Jasmine Pawa, Kethika Kulleperuma, Errol Prasad, Sonia Marchand, K. Dionne, Maxim Trubnikov, Tom Wong, Michael R. Mulvey, and Irene Martin
, Jasmine Pawa, Kethika Kulleperuma, Errol Prasad, Sonia Marchand, K. Dionne, Maxim Trubnikov, Tom Wong, Michael R. Mulvey, and Irene Martin
Table 2
Predicted AMR of gonorrhea positive nucleic acid amplification specimens from Nunavut, 2018–2019*
| Resistance | MICs, mg/L | No. specimens with AMR/no. predicted (%) |
|||
|---|---|---|---|---|---|
| Qikiqtaaluk | Kivalliq | Kitikmeot | Total | ||
| Decreased susceptibility to cephalosporins |
≥0.125 |
0/591 (0) |
1/350 (0.3) |
0/35 (0) |
1/976 (0.1) |
| Intermediate cephalosporin MICs |
0.032–0.063 |
303/591 (51.3) |
49/350 (14.0) |
8/35 (22.9) |
360/976 (36.9) |
| Ciprofloxacin resistant |
≥1 |
298/591 (50.4) |
50/351 (14.2) |
7/35 (20.0) |
355/977 (36.3) |
| Azithromycin resistant |
≥2 |
66/583 (11.3) |
2/350 (0.6) |
0/35 (0) |
68/968 (7.0) |
| *Denominators indicate predicted number of samples with susceptibility for the given antimicrobial. Not all samples were tested for antimicrobial susceptibilities and not all the samples that were tested gave conclusive results. AMR, antimicrobial resistance. | |||||
Page created: February 24, 2021
Page updated: May 18, 2021
Page reviewed: May 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.